HTB homepage • Conference reports • Articles by subject • Subscribe December 2000 Contents Conference reports Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK Treatment strategies in 2000: planning first-line (and therefore, second-line) therapy When should HAART be started? MDR resistance transmission increases in the UK Interferon-gamma treatment in azole-resistant oropharyngeal candidiasis Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD) Clinical issues arising from a single treatment interruption A review of new anti-HIV drugs in development Antiretroviral therapy in children, women and intravenous drug users Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART Child protection issues around starting efavirenz in a mother on maintenance methadone Structured treatment interruptions Adherence and HAART: unique approaches to evaluating and improving adherence discussed Reports on lipodystrophy and metabolic complications Opportunistic infections in the HAART era Antiretrovirals Importance of intensive adherence support for people with HIV-related neurological symptoms Efavirenz side effects become long-term for over one in three ABT-378/r oral formulation available in UK Trimeris, Roche to begin phase III pivotal trials of T-20 HIV fusion inhibitor Women's health Women initiate highly active antiretroviral therapy later than men Association of vitamin A deficiency With cervical squamous intraepithelial lesions in HIV-positive women Side effects Adverse effects of antiretroviral therapy Basic science and immunology Antiretrovirals do not independently affect T-cell count in HIV negative subjects Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells HLA-DR integrates with HIV-1 at chronic disease stage, may raise infectivity Vaccines and microbicides Immune Response Corporation tried to block report on failure of Remune Other news FDA meeting on approving immune therapies: background and comment HIV seroprevalence by anonymous testing in patients with mycobacterium tuberculosis and in tuberculosis contacts HIV-1 Immunogen fails to extend HIV progression-free survival On the web AIDS-related lymphoma PDFs Volume 1 Number 8 November / December 2000 PDF HTB homepage • Conference reports • Articles by subject • Subscribe